Market closed
Neurocrine/$NBIX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Neurocrine
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Ticker
$NBIX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,800
Website
Neurocrine Metrics
BasicAdvanced
$12B
36.68
$3.29
0.33
-
Price and volume
Market cap
$12B
Beta
0.33
52-week high
$157.98
52-week low
$110.95
Average daily volume
1.4M
Financial strength
Current ratio
3.397
Quick ratio
3.063
Long term debt to equity
17.573
Total debt to equity
17.573
Management effectiveness
Return on assets (TTM)
10.46%
Return on equity (TTM)
14.16%
Valuation
Price to earnings (TTM)
36.684
Price to revenue (TTM)
5.145
Price to book
4.66
Price to tangible book (TTM)
4.73
Price to free cash flow (TTM)
21.747
Growth
Revenue change (TTM)
24.81%
Earnings per share change (TTM)
33.20%
3-year revenue growth (CAGR)
27.61%
3-year earnings per share growth (CAGR)
52.92%
What the Analysts think about Neurocrine
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Neurocrine Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Neurocrine Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Neurocrine News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Neurocrine stock?
Neurocrine (NBIX) has a market cap of $12B as of February 23, 2025.
What is the P/E ratio for Neurocrine stock?
The price to earnings (P/E) ratio for Neurocrine (NBIX) stock is 36.68 as of February 23, 2025.
Does Neurocrine stock pay dividends?
No, Neurocrine (NBIX) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next Neurocrine dividend payment date?
Neurocrine (NBIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurocrine?
Neurocrine (NBIX) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.